AIDS Malignancy Consortium
Vincristine Sulfate(AIDS Malignancy Consortium)은 Lugano Classification Limited Stage Hodg 표적 치료제로, Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting, as many cancer cells overexpress folate receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). 차별점: novel immunotherapeutic strategies.
Lugano Classification Limited Stage Hodg
Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Recruiting
Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy
vedotin, rituximab, cyclophosphamide, doxorubic
Lipid Nanoparticles for B‑Cell Acute Lymphoblastic Leukemia Treatment
novel immunotherapeutic strategies
targeting, as many cancer cells overexpress folate receptor
apoptosis was quantified through Annexin V-FITC/PI staining and flow cytometry
biomarkers were assessed
downregulation of survival-related genes (AKT, Bcl-2, mTOR) in the combination group compared to monotherapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
AIDS Malignancy Consortium
Vincristine Sulfate(AIDS Malignancy Consortium)은 Lugano Classification Limited Stage Hodg 표적 치료제로, Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting, as many cancer cells overexpress folate receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). 차별점: novel immunotherapeutic strategies.
Lugano Classification Limited Stage Hodg
Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Recruiting
Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy
vedotin, rituximab, cyclophosphamide, doxorubic
Lipid Nanoparticles for B‑Cell Acute Lymphoblastic Leukemia Treatment
novel immunotherapeutic strategies
targeting, as many cancer cells overexpress folate receptor
apoptosis was quantified through Annexin V-FITC/PI staining and flow cytometry
biomarkers were assessed
downregulation of survival-related genes (AKT, Bcl-2, mTOR) in the combination group compared to monotherapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.